Title : Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.

Pub. Date : 2021 Jun

PMID : 33151783






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Results: Compared with standard EGFR-TKIs, osimertinib was associated with a higher incremental cost of A$118,502, and an incremental benefit of 0.274 QALYs and 0.313 LYs. osimertinib epidermal growth factor receptor Homo sapiens